Robotic Natural Orifice Specimen Extraction Surgery Compared to Robotic Assisted Surgery for Medi… (NCT06454201) | Clinical Trial Compass
CompletedNot Applicable
Robotic Natural Orifice Specimen Extraction Surgery Compared to Robotic Assisted Surgery for Median Rectal Cancer
China150 participantsStarted 2023-01-01
Plain-language summary
The purpose of this study is to evaluate the short-term outcomes of roboric natural orifice specimen extraction surgery (NOSES-II) compared to conventional assisted robotic surgery in the treatment of median rectal cancer. The main question it aims to answer is: is it safe and feasible to perform roboric natural orifice specimen extraction surgery (NOSES-II) for median rectal cancer? What are the advantages of roboric natural orifice specimen extraction surgery (NOSES-II) compared to conventional assisted robotic surgery for median rectal cancer.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The age is more than 18 years old and less than or equal to 85 years old
✓. Eastern Cooperative Oncology Group score ≤2
✓. Preoperative pathological diagnosis of rectal adenocarcinoma
✓. cT1-3NxM0 median rectal cancer defined by preoperative contrast-enhanced MRI
✓. The maximum diameter of tumor ≤5cm on preoperative enhanced MRI
✓. The body can tolerate the operation and sign the informed consent
Exclusion criteria
✕. multiple primary colorectal cancer
✕. recurrent rectal cancer
✕. preoperative neoadjuvant chemoradiotherapy
✕. complicated with intestinal obstruction or intestinal bleeding requiring emergency surgery
✕
What they're measuring
1
The rate of all complications
Timeframe: 1 months after surgery
2
The rate of all complications (Clavien-Dindo grade ≥ III )